Following our well attended and received Conference calls with shareholders on Wednesday May 24th, in particular to the questions on our funding plans. We are as discussed on the call, now able to post on the L.O.M. Web Site the Term Sheet of our $2,250,000 Offering at $2.00. As I said on the call when explaining the need for the Offer the use of funds focus on the efforts to obtain FDA & CE certification for the L.O.M. Retractable Syringe and our Intellectual Property. We are able to provide this Offering as shares remained available after the Rights Issue at $2.00.
Thank You for all your support,
President and CEO
As per requests from shareholders for Clarification:
This offering consists of two opportunities in order to invest and or support L.O.M.
1- To purchase $2.00 shares while shares remain available
2- To support L.O.M. by the way of a secured Loan
L.O.M. Laboratories Inc.
L.O.M. Laboratories Inc. (the “Corporation”), a corporation incorporated under the Business Corporations Act (Alberta). The Corporation is a not a reporting issuer in any province or territory of Canada.
Offering of a combination of class “B” common shares of the Corporation (“Shares”) priced at CAD$2 per share, and promissory notes of the Corporation (“Notes”) for aggregate gross proceeds upon issuance of the Notes and the Shares of not more than CAD$2,250,000. The Shares and Notes shall be issued by way of private placement pursuant to exemptions from applicable Canadian securities laws (the “Offering”).
The term of the Notes shall be two years from the date of issuance (the “Term”). Within 30 days after the end of the Term, the holders of the Notes shall receive, on a pro rata basis, an amount of Shares equal to 0.222 of a Share for each CAD$1 of Notes issued, to a maximum of 500,000 Shares. For greater certainty, the holders of the Promissory Notes will not be entitled to any interest or other payments other than as specifically stated herein.
Investors may subscribe for Shares and/or a Note under the Offering.
The closing (the “Closing”) of the Offering is expected to occur on or about June 30, 2017 (the “Closing Date”) or such other date(s) as the Corporation may determine.
Use of Proceeds:
The Corporation intends to expend the proceeds of the Offering to progress both the FDA & CE Certification with our consultants, CE Medical Experts, in Holland and our 2 Laboratories, Smithers Pria in the UK and TUV Rheinland Group in Germany; to have Shanghai Kindly Enterprise Group in China, complete and use the New Molds for the production of 3,000 LOM Syringes as soon as possible for testing and marketing; and for general corporate and working capital purposes.
A finder’s fee of up to 6% of the gross proceeds of the Offering may be paid, on all or any portion of the funds raised pursuant to the Offering.
Qualification for Subscription:
The Offering will be made to accredited investors or to such other qualified persons under such other prospectus exemptions as the Corporation may approve, provided however, that the Offering will not be made to persons or pursuant to securities laws exemptions that would require either the preparation or the filing of a prospectus, offering memorandum or similar document by the Corporation.
Investors will be required to deliver a completed and executed subscription agreement and payment of the subscription price at least two days prior to Closing.
None of the securities of the Corporation, including the Shares and the Notes, have been or will be listed on any stock exchange, and accordingly, there will be no market for the Shares or the Notes. The Shares and the Notes are subject to applicable hold periods and resale restrictions imposed under applicable securities laws. Since the Corporation is not and will not be a reporting issuer in any jurisdiction in Canada, the hold period may never expire.
For more information please email email@example.com.